Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Anuj K. Agarwala (principal investigator)
Fut, nem toboroz
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás